<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602936</url>
  </required_header>
  <id_info>
    <org_study_id>Jazz BED</org_study_id>
    <nct_id>NCT04602936</nct_id>
  </id_info>
  <brief_title>Solriamfetol in Binge Eating Disorder</brief_title>
  <official_title>Solriamfetol in Binge Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lindner Center of HOPE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lindner Center of HOPE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine&#xD;
      and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating&#xD;
      disorder (BED).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 1-site, randomized, parallel group, double-blind, placebo-controlled, flexible-dose&#xD;
      study in which solriamfetol 37.5-150 mg/day will be administered for 12 weeks to 64&#xD;
      outpatient adults with BED by DSM-5 criteria. The study will have 3 phases: a 1-2 week&#xD;
      Screening phase to evaluate participant eligibility; a 12-week blinded Treatment phase during&#xD;
      which participants will receive solriamfetol or matching placebo; and a 1-week Treatment&#xD;
      Discontinuation phase. During the Treatment phase, participants will be evaluated weekly for&#xD;
      the first 4 weeks and then biweekly for the next 8 weeks. Solriamfetol will be started at&#xD;
      37.5 mg/day. After 1 week, study drug will be increased to 75 mg/day. If a participant&#xD;
      continues to have BED symptoms, study drug may be increased to a maximum of 150 mg/d by&#xD;
      Treatment week 6; after that, study drug dose will be held constant. Efficacy will be&#xD;
      assessed by measuring the weekly frequency of binge-eating episode days with patient&#xD;
      take-home diaries. Regular monitoring of vital signs, laboratory tests, electrocardiograms&#xD;
      (ECGs), adverse events, and suicidality will assess safety&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a 1-site, randomized, parallel group, double-blind, placebo-controlled, flexible-dose study in which solriamfetol 37.5-150 mg/day will be administered for 12 weeks to 64 outpatient adults with BED by DSM-5 criteria</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable is binge-eating day frequency as assessed by the take-home patient diary.</measure>
    <time_frame>Days 1-84</time_frame>
    <description>days with binge eating episodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy variables will include binge-eating episode frequency.</measure>
    <time_frame>Days 1-84</time_frame>
    <description>Number of binge eating episodes per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score on the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOC-BE).</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
    <description>Questions on scale range from 0-4, higher scores are worse. There are 10 questions total. The first 5 questions consist of the &quot;obsessional sub-total&quot; (scores are added together). Questions 6-10 are added together and equal the &quot;compulsion sub-total.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score on the Clinical Global Impression-Severity (CGI-S) and Clinical Global Impressions-Improvement scale (CGI-I).</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
    <description>The Clinical Global Impression - Severity and Improvement scale (CGI-S, CGI-I) is a 7-point scale that requires the clinician to rate the severity and improvement of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. On the CGI-S question, scores range from 1-7, with higher scores being worse (1 = normal, 7 = very severely ill). On the CGI-I questions, scores range from 1-8, with higher scores being worse (1 = no change, 7 = very much worse, 8 = not applicable).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Binge Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Solriamfetol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (i.e., inactive compound for comparison)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solriamfetol</intervention_name>
    <description>Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.</description>
    <arm_group_label>Solriamfetol</arm_group_label>
    <other_name>Sunosi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a &quot;sugar pill&quot;).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Criteria for entering this study will include all of the following:&#xD;
&#xD;
          1. Participants will meet DSM-5 criteria for a diagnosis of BED. These criteria are:&#xD;
&#xD;
               1. Recurrent episodes of binge eating. Both of the following characterize a&#xD;
                  binge-eating episode: 1. Eating, in a discrete period (e.g., within 2 hours), an&#xD;
                  amount of food that is definitely larger than most people would eat in a similar&#xD;
                  period under similar conditions; and 2. A sense of lack of control over the&#xD;
                  eating (e.g., a feeling that one cannot stop eating or control what or how much&#xD;
                  one is eating).&#xD;
&#xD;
               2. The binge-eating episodes are associated with at least three of the following:&#xD;
                  eating much more rapidly than normal; eating until uncomfortably full; eating&#xD;
                  large amounts of food when not feeling physically hungry; eating alone because of&#xD;
                  being embarrassed by how much one is eating; feeling disgusted with oneself,&#xD;
                  depressed, or feeling very guilty after overeating.&#xD;
&#xD;
               3. Marked distress regarding binge eating.&#xD;
&#xD;
               4. The binge eating occurs, on average, at least one day a week for 3 months.&#xD;
&#xD;
               5. The episodes of binge eating do not occur exclusively during the course of&#xD;
                  bulimia nervosa or anorexia nervosa.&#xD;
&#xD;
          2. In addition, to ensure that BED is of at least moderate severity, participants will&#xD;
             report at least three binge-eating days per week during the 1 week prior to initiation&#xD;
             of study medication, prospectively documented in take-home binge diaries. A&#xD;
             binge-eating day (or binge day) is a day during which at least one binge-eating&#xD;
             episode occurs.&#xD;
&#xD;
          3. Men or women, through the ages of 18 and 65 years, inclusive.&#xD;
&#xD;
        Exclusion Criteria: Criteria for exclusion from this study will be any of the following:&#xD;
&#xD;
          1. Have a current diagnosis of bulimia nervosa or anorexia nervosa.&#xD;
&#xD;
          2. Women who are pregnant, lactating, or of childbearing potential who are not using&#xD;
             adequate contraceptive measures. The following are considered adequate methods of&#xD;
             birth control: 1. intrauterine device (IUD); 2. barrier protection; 3. a contraceptive&#xD;
             implantation system (Norplant); 4. oral contraceptive pills; 5. a surgically sterile&#xD;
             patient; and 6. abstinence. All female participants will have a negative pregnancy&#xD;
             test prior to randomization.&#xD;
&#xD;
          3. Individuals who are displaying clinically significant suicidality or homicidality.&#xD;
&#xD;
          4. Individuals who are receiving a psychological (e.g., supportive psychotherapy,&#xD;
             cognitive behavior therapy, interpersonal therapy) or weight loss (e.g., Weight&#xD;
             Watchers) intervention for BED that was begun within the 3 months before study entry.&#xD;
             Individuals beginning such treatment more than 3 months prior to study entry may be&#xD;
             enrolled as long as they to agree to not make any changes to the frequency or nature&#xD;
             of their treatment during the course of the drug trial.&#xD;
&#xD;
          5. A DSM-IV-TR diagnosis of substance abuse or dependence (except nicotine abuse or&#xD;
             dependence) within the 6 months prior to randomization.&#xD;
&#xD;
          6. Individuals who have used psychostimulants to facilitate fasting or dieting as a part&#xD;
             of their eating disorder within the past 6 months, individuals who have misused&#xD;
             psychostimulants within the past 6 months, and individuals who have a drug screen at&#xD;
             the Screening visit positive for psychostimulants.&#xD;
&#xD;
          7. Individuals with a lifetime DSM-IV-TR history of psychosis, mania or hypomania, or&#xD;
             dementia.&#xD;
&#xD;
          8. Individuals with a history of any psychiatric disorder that might interfere with a&#xD;
             diagnostic assessment, treatment, or study compliance.&#xD;
&#xD;
          9. Individuals who have a body mass index (BMI) â‰¤ 18 mg/kg2&#xD;
&#xD;
         10. Clinically unstable medical disease, including cardiovascular, hepatic, renal,&#xD;
             gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease.&#xD;
&#xD;
         11. Have a history of a structural cardiac abnormality, cardiomyopathy, serious heart&#xD;
             rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular&#xD;
             problem.&#xD;
&#xD;
         12. History of seizures, including clinically febrile seizures in childhood.&#xD;
&#xD;
         13. Have uncontrolled hypertension (&gt;160/100) or tachycardia (heart rate &gt;110).&#xD;
&#xD;
         14. Have an ECG with significant arrhythmias or conduction abnormalities, which in the&#xD;
             opinion of the physician investigator precludes study participation.&#xD;
&#xD;
         15. Have clinically relevant abnormal laboratory results, specifically including&#xD;
             hypokalemia.&#xD;
&#xD;
         16. Have a history of narcolepsy or obstructive sleep apnea, or currently receiving&#xD;
             treatment with an alerting agent.&#xD;
&#xD;
         17. Individuals requiring treatment with any drug which might interact adversely with or&#xD;
             obscure the action of the study medication. This includes warfarin, anticonvulsants,&#xD;
             clonidine, theophylline, and pseudoephedrine.&#xD;
&#xD;
         18. Individuals who have received any psychotropic medications (other than hypnotics)&#xD;
             within four weeks prior to randomization, including antidepressants (including&#xD;
             monoamine oxidase inhibitors), antipsychotics, mood stabilizers, or psychostimulants.&#xD;
&#xD;
         19. Individuals who have received investigational medications or depot neuroleptics within&#xD;
             three months prior to randomization.&#xD;
&#xD;
         20. Individuals who have a known allergy to solriamfetol or its constituents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Guerdjikova</last_name>
    <phone>513-536-0700</phone>
    <email>anna.guerdjikova@lindnercenter.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genie Groff</last_name>
    <phone>513-536-0700</phone>
    <email>genie.groff@lindnercenter.org</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

